A high rate of RCM-histopathological concordance was observed, with 58.6% and 88.2% of biopsies avoided in adults and children, respectively.
R1 RCM launches revenue operating system Phare OS, integrating AI to improve revenue cycle efficiency and payer connectivity.
Discover key highlights from RCM Technologies' Q3 2025 earnings: record engineering backlog, growth strategies, and outlook for robust 2026 results.
Zacks Investment Research on MSN
Is Trending Stock RCM Technologies, Inc. (RCMT) a Buy Now?
RCM Technologies, Inc. (RCMT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Market is projected to grow from USD 449.83 billion in 2024 to USD 28560 billion by 2035, registering an impressive CAGR of ...
RCM Technologies Inc (RCMT) reports strong future demand with record engineering backlogs, while navigating financial impacts from excess medical costs and administrative issues.
Prochant has launched a new set of artificial intelligence (AI) capabilities that it says brings automation and intelligence ...
RCM Technologies (NASDAQ: RCMT) is preparing to release its quarterly earnings on Wednesday, 2025-11-05. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...
The November reading of 43.9 marks a steep 9% monthly decline and a widening gap between investors and non-investors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback